Our Featured Research Page lists cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers. Sign up for our community newsletter to stay up to date on the latest hereditary cancer research.
Featured Studies Results
Study Type: Treatment
NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer
Clinicaltrials.gov identifier:
NCT05498272
Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
Clinicaltrials.gov identifier:
NCT05417594
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
Nipple Sparing Mastectomy With Immediate Implant-Based Reconstruction for Women With Early-Stage Breast Cancer
Clinicaltrials.gov identifier:
NCT05720039
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
Clinicaltrials.gov identifier:
NCT04030559
Treatment
High-risk localized prostate cancer
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
Clinicaltrials.gov identifier:
NCT04550494
Treatment
Treatment study for people with advanced solid tumors
Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)
Clinicaltrials.gov identifier:
NCT04038502
Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
Clinicaltrials.gov identifier:
NCT04644068
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations
Clinicaltrials.gov identifier:
NCT04042831
Treatment
Treatment study for people diagnosed with metastatic biliary tract (bile duct) cancer and who have an inherited or tumor mutation in ATM, BRCA 1/2, BRIP1, CHEK2, RAD51C, RAD51D, PALB2, PTEN, NBN and others
If you would like a more in-depth search, visit our In-Depth Search Tool that searches for studies in FORCE’s database and in clinicaltrials.gov
Sponsored By:
